Is dermatomyositis in patients with rheumatoid arthritis induced by anti-TNF-α therapy?

Clinical Rheumatology

Volumn 30, Issue 3, 2011, Pages 439-440

  Brunasso, Alexandra Maria Giovanna ^a,b   Massone, Cesare ^b  

^a GALLIERA HOSPITAL   (Italy)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CHLOROQUINE; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AUTOIMMUNITY; AXONAL NEUROPATHY; CLINICAL EXAMINATION; DEMYELINATING NEUROPATHY; DERMATOMYOSITIS; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; LETTER; MYOPATHY; MYOSITIS; NEUROPATHY; POLYMYOSITIS; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DERMATOMYOSITIS; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954608019     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1661-6     Document Type: Letter

References (10)

1. T Nagashima S Minota 2010 Is polymyositis or dermatomyositis in patients with rheumatoid arthritis induced or unveiled by anti-tumor necrosis factor treatment? Clin Rheumatol 29 819 820 20405301 10.1007/s10067-010-1467-6
2. E Martínez-Cordero DE León LA Ortega 2001 Association of polymyositis with rheumatoid arthritis Rheumatol Int 20 119 23 11354559 10.1007/s002960000084 (Pubitemid 32250124)
3. T Nagashima H Sato S Minota 2009 Destructive arthropathy associated with dermatomyositis sine myositis positive for anti-Jo-1 and anti-cyclic citrullinated peptide antibodies J Rheumatol 36 2133 2143 19738232 10.3899/jrheum.090183
4. Sattar MA, Al-Sughyer AA, Siboo R (1988) Coexistence of rheumatoid arthritis, ankylosing spondylitis and dermatomyositis in a patient with diabetes mellitus and the associated linked HLA antigens. Br J Rheumatol 27:146-149. (Pubitemid 18098308)
5. LR Ginn JP Lin PH Plotz SJ Bale RL Wilder A Mbauya FW Miller 1998 Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases Arthritis Rheum 41 400 405 9506566 10.1002/1529-0131(199803)41:3<400::AID-ART4>3.0. CO;2-5 1:STN:280:DyaK1c7msFCisg%3D%3D (Pubitemid 28128763)
6. AM Brunasso GL Scocco C Massone 2010 Dermatomyositis during adalimumab therapy for rheumatoid arthritis J Rheumatol 37 1549 1550 20595297 10.3899/jrheum.091413 1:CAS:528:DC%2BC3cXhtVKlu7%2FJ
7. IR Edwards JK Aronson 2000 Adverse drug reactions: definitions, diagnosis, and management Lancet 356 1255 1259 11072960 10.1016/S0140-6736(00) 02799-9 1:CAS:528:DC%2BD3cXot1agsr8%3D
8. U Kiltz C Fendler J Braun 2008 Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy-three examples J Rheumatol 35 2074 2076 18843765
9. Y Ishikawa N Yukawa K Ohmura Y Hosono Y Imura D Kawabata, et al. 2010 Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature Clin Rheumatol 29 563 566 20143116 10.1007/s10067-009-1370-1
10. AH Harald Z Bernard 2006 Evolution of dermatomyositis during therapy with a tumor necrosis factor α inhibitor Arthritis Rheum 55 982 984 10.1002/art.22358 (Pubitemid 44917476)